WSTNYSEHealthcare

WEST PHARMACEUTICAL SERVICES INC

Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.

Latest price

$399.81

+1.87%

Alpha Vantage · 11/6/2026

Industry: Medical Instruments & SuppliesCategory: Domestic Common StockCurrency: USDNews: 1 recent

Analyze WST free

One-year price history

Adjusted daily closes · 252 observations · as of Nov 6, 2026

Historical data, not a forecast

1 month

+10.1%

3 months

+13.5%

6 months

+22.8%

1 year

+45.7%

Year to date

+45.6%

52-week range

$230.63 – $416.67

Fundamental snapshot

Latest reported period: Sep 30, 2026

Sharadar reported data

Market cap

$27.85B

P/E

43.6

P/B

9.4

P/S

8.2

Revenue

$3.4B

Net income

$638.9M

Diluted EPS

8.91

Gross margin

37.60%

Net margin

18.80%

Return on equity

21.10%

Total debt

$305M

Cash

$464.1M

Free cash flow

$580.3M

Latest eight reported quarters

Reported quarterly values, newest first

Period	Revenue	Net income	Gross margin	Net margin	Free cash flow
Sep 30, 2026	$874.5M	$214M	39.70%	24.50%	$277.3M
Jun 30, 2026	$872.3M	$154M	37.70%	17.70%	$80.8M
Mar 31, 2026	$844.9M	$138.8M	35.10%	16.40%	$47.2M
Dec 31, 2025	$805M	$132.1M	37.80%	16.40%	$175M
Sep 30, 2025	$804.6M	$140M	36.60%	17.40%	$133.9M
Jun 30, 2025	$766.5M	$131.8M	35.70%	17.20%	$101.9M
Mar 31, 2025	$698M	$89.8M	33.20%	12.90%	$58.1M
Dec 31, 2024	$748.8M	$130.1M	36.50%	17.40%	$85.2M

Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.

Recent WST news

All market news

Dealroom·Oct 28, 202652 signal

West Pharmaceutical draws $200M term loan in $950M refinancing

West Pharmaceutical Services has secured a new $950 million unsecured credit facility, including a $200 million term loan and a $750 million revolving credit line, with Bank of America as the administrative agent. This refinancing replaces their 2019 credit agreement and aims to provide liquidity for working capital, acquisitions, stock repurchases, and debt repayment. The move reflects the company's strong sales growth and continued investment in injectable drug delivery capacity.

Original source